Cargando…

Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization

BACKGROUND: Adults with comorbid illness are known to be at excess risk of IPD. We evaluated the burden of IPD in adults, with and without comorbidity, during the period before and after introduction of PCV13 in children and selected adults. METHODS: We employed a retrospective cohort design and dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelton, Stephen I, Bornheimer, Rebecca, Shea, Kimberly M, Sato, Reiko, Weycker, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630750/
http://dx.doi.org/10.1093/ofid/ofx163.1195
_version_ 1783269283772497920
author Pelton, Stephen I
Bornheimer, Rebecca
Shea, Kimberly M
Sato, Reiko
Weycker, Derek
author_facet Pelton, Stephen I
Bornheimer, Rebecca
Shea, Kimberly M
Sato, Reiko
Weycker, Derek
author_sort Pelton, Stephen I
collection PubMed
description BACKGROUND: Adults with comorbid illness are known to be at excess risk of IPD. We evaluated the burden of IPD in adults, with and without comorbidity, during the period before and after introduction of PCV13 in children and selected adults. METHODS: We employed a retrospective cohort design and data from a large US healthcare claims repository. The study population included all adults aged ≥18 years who had ≥1 day of health benefits at any time from 2007–2015, and who met minimum criteria for characterizing comorbidity profiles. Study subjects were stratified by age (18–49, 50–64, and ≥65 years) and risk profile (“at-risk”, “high-risk”, and “healthy”) based on ACIP-identified indications for pneumococcal vaccination. Episodes of IPD were identified in each year of the study period, and rate ratios comparing IPD incidence in persons with at-risk and high-risk conditions, respectively, vs. healthy persons, were computed. RESULTS: A substantial decline in IPD was observed in 2013–2015 compared with 2007–2010 in healthy, at-risk, and high-risk adults in all age groups. However, the proportional decline was lower in those with high- risk and at-risk conditions, resulting in an increased rate ratio for adults with comorbid conditions (Table). CONCLUSION: IPD burden declined from the pre-PCV13 era. This decline was greatest in healthy adults (vs.. those with at-risk or high-risk conditions); adults with comorbid conditions, especially those ≥65 years old, appear to have benefited least from the direct and indirect impacts of PCV13 immunization. Greater understanding as to which serotypes cause disease in adults with comorbid conditions and which host factors in individuals predispose to IPD is needed to develop additional prevention strategies for high-risk groups. DISCLOSURES: S. I. Pelton, Pfizer: Board Member and Grant Investigator, Consulting fee, Research grant and Speaker honorarium; Merck vaccines: Board Member, Consulting fee and Speaker honorarium; GSK: Board Member, Consulting fee and Speaker honorarium; Sequiris: Board Member, Consulting fee and Speaker honorarium; R. Bornheimer, Pfizer, Inc: Consultant, Consulting fee; K. M. Shea, Pfizer, Inc: Consultant and Grant Investigator, Consulting fee and Grant recipient; R. Sato, Pfizer, Inc: Employee and Shareholder, Salary; D. Weycker, Pfizer, Inc: Consultant, Consulting fee
format Online
Article
Text
id pubmed-5630750
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56307502017-11-07 Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization Pelton, Stephen I Bornheimer, Rebecca Shea, Kimberly M Sato, Reiko Weycker, Derek Open Forum Infect Dis Abstracts BACKGROUND: Adults with comorbid illness are known to be at excess risk of IPD. We evaluated the burden of IPD in adults, with and without comorbidity, during the period before and after introduction of PCV13 in children and selected adults. METHODS: We employed a retrospective cohort design and data from a large US healthcare claims repository. The study population included all adults aged ≥18 years who had ≥1 day of health benefits at any time from 2007–2015, and who met minimum criteria for characterizing comorbidity profiles. Study subjects were stratified by age (18–49, 50–64, and ≥65 years) and risk profile (“at-risk”, “high-risk”, and “healthy”) based on ACIP-identified indications for pneumococcal vaccination. Episodes of IPD were identified in each year of the study period, and rate ratios comparing IPD incidence in persons with at-risk and high-risk conditions, respectively, vs. healthy persons, were computed. RESULTS: A substantial decline in IPD was observed in 2013–2015 compared with 2007–2010 in healthy, at-risk, and high-risk adults in all age groups. However, the proportional decline was lower in those with high- risk and at-risk conditions, resulting in an increased rate ratio for adults with comorbid conditions (Table). CONCLUSION: IPD burden declined from the pre-PCV13 era. This decline was greatest in healthy adults (vs.. those with at-risk or high-risk conditions); adults with comorbid conditions, especially those ≥65 years old, appear to have benefited least from the direct and indirect impacts of PCV13 immunization. Greater understanding as to which serotypes cause disease in adults with comorbid conditions and which host factors in individuals predispose to IPD is needed to develop additional prevention strategies for high-risk groups. DISCLOSURES: S. I. Pelton, Pfizer: Board Member and Grant Investigator, Consulting fee, Research grant and Speaker honorarium; Merck vaccines: Board Member, Consulting fee and Speaker honorarium; GSK: Board Member, Consulting fee and Speaker honorarium; Sequiris: Board Member, Consulting fee and Speaker honorarium; R. Bornheimer, Pfizer, Inc: Consultant, Consulting fee; K. M. Shea, Pfizer, Inc: Consultant and Grant Investigator, Consulting fee and Grant recipient; R. Sato, Pfizer, Inc: Employee and Shareholder, Salary; D. Weycker, Pfizer, Inc: Consultant, Consulting fee Oxford University Press 2017-10-04 /pmc/articles/PMC5630750/ http://dx.doi.org/10.1093/ofid/ofx163.1195 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Pelton, Stephen I
Bornheimer, Rebecca
Shea, Kimberly M
Sato, Reiko
Weycker, Derek
Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title_full Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title_fullStr Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title_full_unstemmed Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title_short Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
title_sort excess risk of invasive pneumococcal disease (ipd) persists in adults with comorbid conditions in the era of pcv13 childhood and adult immunization
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630750/
http://dx.doi.org/10.1093/ofid/ofx163.1195
work_keys_str_mv AT peltonstepheni excessriskofinvasivepneumococcaldiseaseipdpersistsinadultswithcomorbidconditionsintheeraofpcv13childhoodandadultimmunization
AT bornheimerrebecca excessriskofinvasivepneumococcaldiseaseipdpersistsinadultswithcomorbidconditionsintheeraofpcv13childhoodandadultimmunization
AT sheakimberlym excessriskofinvasivepneumococcaldiseaseipdpersistsinadultswithcomorbidconditionsintheeraofpcv13childhoodandadultimmunization
AT satoreiko excessriskofinvasivepneumococcaldiseaseipdpersistsinadultswithcomorbidconditionsintheeraofpcv13childhoodandadultimmunization
AT weyckerderek excessriskofinvasivepneumococcaldiseaseipdpersistsinadultswithcomorbidconditionsintheeraofpcv13childhoodandadultimmunization